ReviewPharmacogenomics and personalized medicine2019
Update on the pharmacogenomics of pain management.
Review in Pharmacogenomics and personalized medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 41 citations in OpenAlex.
- Evolving Paradigms in Cancer Pain Management: From Opioid-Centric Care to Multimodal and Personalized Strategies.Cancers · 2026Review
- Opioid Use Following Spine Surgery: Strategies for a Multimodal Approach To Pain Management.Current pain and headache reports · 2026Review
- Comparison of Pecto-Intercostal Fascial Block Vs Transversus Thoracic Plane Block and Their Pharmacogenomics for Pain Management After Sternotomy in Cardiac Surgery: A Narrative Review.Journal of pain research · 2026Review
- Personalized Multimodal and Opioid-Sparing Analgesia for Postoperative Pain Management: Enhancing Recovery and Addressing the Post-Discharge Gap.Journal of pain research · 2026Review
- Integrating genetic insights into pain management and opioid use optimization in chronic pain and substance abuse populations.Exploratory research in clinical and social pharmacy · 2025Article
- Review
- General Innovations in Pain Management.Journal of clinical medicine · 2025Review
- The Role of Pharmacogenomics in Optimizing Ketamine Therapy for Post-Amputation Pain.Reports (MDPI) · 2025Review
- Opioid Use in Cancer Pain Management: Navigating the Line Between Relief and Addiction.International journal of molecular sciences · 2025Review
- Moving Away from One-Size-Fits-All: Assessing the Use of Pharmacogenetic-Guided Medication Therapy in Pediatric Patients with Chronic Pain.Children (Basel, Switzerland) · 2025Article
- Genetic Modifiers Associated with Vaso-Occlusive Crises and Acute Pain Phenomena in Sickle Cell Disease: A Scoping Review.International journal of molecular sciences · 2025Article
- Review
- Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management.Health services insights · 2025Article
- Review
- [Design of a Tool for Patient Classification Based on Pharmacotherapeutic Attitudes].Farmaceuticos comunitarios · 2024Observational
- Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management.Biomedicines · 2024Review
- Pharmacogenetic landscape of pain management variants among Mediterranean populations.Frontiers in pharmacology · 2024Article
- Risk Factors Associated With Drug-Related Side Effects in Children: A Scoping Review.Global pediatric health · 2024Article
- Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions.Irish journal of medical science · 2023Review
- The Role of Pharmacogenomics in Opioid Prescribing.Current treatment options in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics is the study of genetic variants that impact drug effects through changes in a drug's pharmacokinetics and pharmacodynamics. Pharmacogenomics is being integrated into clinical pain management practice because variants in individual genes can be predictive of how a patient may respond to a drug treatment. Pain is subjective and is considered challenging to treat. Furthermore, pain patients do not respond to treatments in the same way, which makes it hard to issue a consistent treatment regimen for all pain conditions. Pharmacogenomics would bring consistency to the subjective nature of pain and could revolutionize the field of pain management by providing personalized medical care tailored to each patient based on their gene variants. Additionally, pharmacogenomics offers a solution to the opioid crisis by identifying potentially opioid-vulnerable patients who could be recommended a nonopioid treatment for their pain condition. The integration of pharmacogenomics into clinical practice creates better and safer healthcare practices for patients. In this article, we provide a comprehensive history of pharmacogenomics and pain management, and focus on up to date information on the pharmacogenomics of pain management, describing genes involved in pain, genes that may reduce or guard against pain and discuss specific pain management drugs and their genetic correlations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.